China Beckons: Sun Joins Indian Firms Priming For Larger Presence
Evolving regulations and emerging opportunities appear to have put China firmly on the radar of several frontline Indian firms. Sun Pharma is the latest to join those seeking a larger play in the Asian market.
You may also be interested in...
Lupin has built on a recent alliance in China with Foncoo by agreeing a further partnership for the Chinese market, this time with Yabao Pharmaceutical.
India's Sun has licensed out treatments for psoriasis and dry eye to a new partner for selected Asian markets and China, which it expects to emerge as a key market for its products.
Alembic has firmed up a joint venture to tap into emerging opportunities in China amid evolving regulations there, and believes the market holds significant promise despite rising price pressures.